These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31965135)

  • 1. Advanced nanotechnology for hypoxia-associated antitumor therapy.
    Zhao L; Fu C; Tan L; Li T; Zhong H; Meng X
    Nanoscale; 2020 Feb; 12(5):2855-2874. PubMed ID: 31965135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative Strategies for Hypoxic-Tumor Photodynamic Therapy.
    Li X; Kwon N; Guo T; Liu Z; Yoon J
    Angew Chem Int Ed Engl; 2018 Sep; 57(36):11522-11531. PubMed ID: 29808948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hypoxia: Revival of Old Remedies.
    Vilaplana-Lopera N; Besh M; Moon EJ
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advancements of Nanotechnology-Based Strategies for Overcoming Tumor Microenvironment Hypoxia.
    Wu J; Song J; Yin X; Tang J; Zhang J; Wang X; Ji Y; Zhao Y; Chen D; Sheng J; Bai X; Liang T
    Front Biosci (Landmark Ed); 2022 May; 27(5):145. PubMed ID: 35638412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting hypoxic tumor microenvironment in pancreatic cancer.
    Tao J; Yang G; Zhou W; Qiu J; Chen G; Luo W; Zhao F; You L; Zheng L; Zhang T; Zhao Y
    J Hematol Oncol; 2021 Jan; 14(1):14. PubMed ID: 33436044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting Hypoxia and Chemotherapy-Induced Cancer Cell Metastasis under a Valid Therapeutic Effect by an Assistance of Biomimetic Oxygen Delivery.
    Jiang MS; Yin XY; Qin B; Xuan SY; Yuan XL; Yin H; Zhu C; Li X; Yang J; Du YZ; Luo LH; You J
    Mol Pharm; 2019 Nov; 16(11):4530-4541. PubMed ID: 31617723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response.
    Francis A; Venkatesh GH; Zaarour RF; Zeinelabdin NA; Nawafleh HH; Prasad P; Buart S; Terry S; Chouaib S
    Crit Rev Immunol; 2018; 38(6):505-524. PubMed ID: 31002604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conquering the Hypoxia Limitation for Photodynamic Therapy.
    Wan Y; Fu LH; Li C; Lin J; Huang P
    Adv Mater; 2021 Dec; 33(48):e2103978. PubMed ID: 34580926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.
    Song P; Yao X; Zhong T; Zhang S; Guo Y; Ren W; Huang D; Duan XC; Yin YF; Zhang SS; Zhang X
    Oncotarget; 2016 Jul; 7(30):48467-48480. PubMed ID: 27366947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them.
    Tan Q; Saggar JK; Yu M; Wang M; Tannock IF
    Cancer J; 2015; 21(4):254-62. PubMed ID: 26222076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-temperature PTT/CDT coordination nanoplatform realizing exacerbated hypoxia for enhancing hypoxia-activated chemotherapy to overcome tumor drug resistance.
    Chang P; Guo Y; Chen D; Li K; Wang W; Yang Z; Ma J; Zeng Y; Zhan W; Zhan Y
    J Nanobiotechnology; 2024 Jun; 22(1):374. PubMed ID: 38926723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum(IV) complex-based two-in-one polyprodrug for a combinatorial chemo-photodynamic therapy.
    Guo D; Xu S; Huang Y; Jiang H; Yasen W; Wang N; Su Y; Qian J; Li J; Zhang C; Zhu X
    Biomaterials; 2018 Sep; 177():67-77. PubMed ID: 29885587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirapazamine-embedded polyplatinum(iv) complex: a prodrug combo for hypoxia-activated synergistic chemotherapy.
    Guo D; Xu S; Yasen W; Zhang C; Shen J; Huang Y; Chen D; Zhu X
    Biomater Sci; 2020 Jan; 8(2):694-701. PubMed ID: 31777870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azodyes as markers for tumor hypoxia imaging and therapy: An up-to-date review.
    Kumari R; Sunil D; Ningthoujam RS; Kumar NA
    Chem Biol Interact; 2019 Jul; 307():91-104. PubMed ID: 31047917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-activated nanomedicines for effective cancer therapy.
    Zhou M; Xie Y; Xu S; Xin J; Wang J; Han T; Ting R; Zhang J; An F
    Eur J Med Chem; 2020 Jun; 195():112274. PubMed ID: 32259703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
    Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
    Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting hypoxia in cancer therapy.
    Wilson WR; Hay MP
    Nat Rev Cancer; 2011 Jun; 11(6):393-410. PubMed ID: 21606941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current developments in nanotechnology for improved cancer treatment, focusing on tumor hypoxia.
    Phung CD; Tran TH; Pham LM; Nguyen HT; Jeong JH; Yong CS; Kim JO
    J Control Release; 2020 Aug; 324():413-429. PubMed ID: 32461115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current advances in modulating tumor hypoxia for enhanced therapeutic efficacy.
    Liu Z; Liu X; Zhang W; Gao R; Wei H; Yu CY
    Acta Biomater; 2024 Mar; 176():1-27. PubMed ID: 38232912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.